Belanger Aimee E, Lai Angel, Brackman Marcia A, LeBlanc Donald J
Infectious Disease Research, Lilly Research Laboratories, Eli Lilly and Company, Drop Code 0428, Indianapolis, IN 46285, USA.
Antimicrob Agents Chemother. 2002 Aug;46(8):2507-12. doi: 10.1128/AAC.46.8.2507-2512.2002.
Described here are the development and validation of a novel approach to identify genes encoding drug targets in Streptococcus pneumoniae. The method relies on the use of an ordered genomic library composed of PCR amplicons that were generated under error-prone conditions so as to introduce random mutations into the DNA. Since some of the mutations occur in drug target-encoding genes and subsequently affect the binding of the drug to its respective cellular target, amplicons containing drug targets can be identified as those producing drug-resistant colonies when transformed into S. pneumoniae. Examination of the genetic content of the amplicon giving resistance coupled with bioinformatics and additional genetic approaches could be used to rapidly identify candidate drug target genes. The utility of this approach was verified by using a number of known antibiotics. For drugs with single protein targets, amplicons were identified that rendered S. pneumoniae drug resistant. Assessment of amplicon composition revealed that each of the relevant amplicons contained the gene encoding the known target for the particular drug tested. Fusidic acid-resistant mutants that resulted from the transformation of S. pneumoniae with amplicons containing fusA were further characterized by sequence analysis. A single mutation was found to occur in a region of the S. pneumoniae elongation factor G protein that is analogous to that already implicated in other bacteria as being associated with fusidic acid resistance. Thus, in addition to facilitating the identification of genes encoding drug targets, this method could provide strains that aid future mechanistic studies.
本文描述了一种用于鉴定肺炎链球菌中编码药物靶点的基因的新方法的开发与验证。该方法依赖于使用由PCR扩增子组成的有序基因组文库,这些扩增子是在易错条件下生成的,以便将随机突变引入DNA。由于一些突变发生在编码药物靶点的基因中,随后会影响药物与其相应细胞靶点的结合,因此当将含有药物靶点的扩增子转化到肺炎链球菌中时,可将其鉴定为产生耐药菌落的扩增子。对产生耐药性的扩增子的遗传内容进行检测,并结合生物信息学和其他遗传学方法,可用于快速鉴定候选药物靶点基因。通过使用多种已知抗生素验证了该方法的实用性。对于具有单一蛋白质靶点的药物,鉴定出了使肺炎链球菌产生耐药性的扩增子。对扩增子组成的评估表明,每个相关扩增子都包含编码所测试特定药物已知靶点的基因。通过序列分析对用含有fusA的扩增子转化肺炎链球菌产生的耐夫西地酸突变体进行了进一步表征。在肺炎链球菌延伸因子G蛋白的一个区域发现了一个单一突变,该区域与其他细菌中已涉及的与耐夫西地酸抗性相关的区域类似。因此,除了有助于鉴定编码药物靶点的基因外,该方法还可以提供有助于未来机制研究的菌株。